Adalimumab: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #144 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:TNF inhibitors]] | |||
[[Category:Biologics]] | |||
[[Category:DMARDs]] | |||
[[Category:Immunosuppressants]] | |||
[[Category:Monoclonal antibodies]] | |||
Latest revision as of 10:43, 23 May 2026
Adalimumab
Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Rheumatoid arthritis0, Psoriatic arthritis0, Ankylosing spondylitis0, Crohn's disease0, Ulcerative colitis0, Moderate-to-severe plaque psoriasis0, Hidradenitis suppurativa0, Non-infectious uveitis0, Juvenile idiopathic arthritis0
Pharmacy
Starting dose
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week
Preparations
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths
US FDA Max
40 mg every week (selected indications); otherwise 40 mg every other week
Pharmacology
Routes
Subcutaneous
Onset
Symptomatic effect within weeks; full response by 12-24 weeks
Duration
2 weeks per dose
Half-life
~14 days[1]
Bioavailability
~64% from SC depot[1]
Pregnancy
Generally continued through pregnancy when needed for disease control; placental transfer is minimal in the first trimester but increases in third trimester, so dose timing around delivery and considerations for live-vaccine schedule in the infant are standard.[citation needed]
Legal status
Purported mechanism
Adalimumab is a fully human recombinant IgG1 monoclonal antibody that binds tumor necrosis factor α (TNF-α), neutralizing its interaction with TNF receptors 1 and 2 and lysing TNF-α-expressing cells via Fc-mediated complement and ADCC; the net effect is broad suppression of TNF-driven inflammatory signaling in immune-mediated diseases.0 Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Humira (adalimumab), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s415lbl.pdf